This story has been updated with comments from a company earnings call.

NEW YORK (Genomeweb News) – Vermillion reported today that its second quarter revenues were $535,000, up 65 percent from $324,000 in Q2 2014 but falling short of the average Wall Street estimate of $1.2 million.

The company posted product revenue of $535,000, up 153 percent from $211,000 in Q2 2014. It had no license revenue, compared to $113,000 in the year-ago period.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.